# Cumberland Pharmaceuticals Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cumberland Pharmaceuticals Inc). ## Overview Cumberland Pharmaceuticals Inc. is a U.S.-based specialty pharmaceutical company that acquires, develops, and commercializes branded prescription medicines. Its portfolio is concentrated in hospital acute care, gastroenterology, and oncology, where it can market to relatively concentrated prescriber bases with targeted sales teams. The company sells products such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Tacilia, and it also earns other revenue from licensing, milestone payments, and related arrangements. Cumberland combines U.S. commercial execution with international partnerships to expand access to its brands outside the United States. The business is built around branded products, lifecycle management, and selective development or acquisition of additional assets. ## Products & services • Acetadote injection for acetaminophen poisoning • Caldolor ibuprofen injection for pain and fever • Kristalose lactulose oral solution for constipation • Sancuso transdermal for chemotherapy-related nausea • Vibativ injection for serious bacterial infections • Vaprisol injection for hyponatremia in hospitalized patients • Tacilia oral capsule for H. pylori infection - **Hospital acute care** (45%) — Injectable and inpatient-focused brands used in hospital settings for urgent or monitored treatment. - **Gastroenterology** (20%) — Products used for digestive and gastrointestinal conditions, including constipation and H. pylori treatment. - **Oncology supportive care** (15%) — Therapies used to support cancer patients, especially for chemotherapy-related side effects. - **Anti-infective and specialty infectious disease** (10%) — Hospital-use anti-infective products for serious bacterial infections and related indications. - **Other revenue and partnerships** (10%) — Milestone payments, licensing income, contract services, and other non-product revenue. - Acetadote injection for acetaminophen overdose treatment - Caldolor injection for pain and fever management - Kristalose oral lactulose for constipation treatment - Sancuso transdermal patch for chemotherapy-induced nausea and vomiting - Vibativ injection for serious hospital-acquired bacterial infections - Vaprisol injection for euvolemic and hypervolemic hyponatremia - Tacilia oral capsule for H. pylori infection ## Customers Cumberland primarily sells to wholesale pharmaceutical distributors in the United States, which then supply hospitals, clinics, surgery centers, and retail pharmacies. Its brands are also influenced by hospital buyers, group purchasing organizations, pharmacy benefit managers, and managed care organizations that determine formulary access and reimbursement. In practice, the end users are physicians and care teams in acute care, gastroenterology, and oncology settings, but the commercial decision-makers include wholesalers and institutional purchasing organizations. Internationally, the company relies on partners with regulatory and commercial capabilities to register and distribute products in local markets. This makes customer demand highly dependent on institutional access, reimbursement, and product inclusion on formularies. - **U.S. pharmaceutical wholesalers** (primary) — Primary buyers that purchase branded products in bulk and distribute them to hospitals, clinics, and pharmacies. - **Hospitals and health systems** (primary) — Institutional end users for acute-care injectables such as Acetadote, Caldolor, and Vibativ, where clinical need and formulary placement drive use. - **Payors and PBMs** (primary) — Indirect customers that influence rebates, formulary inclusion, and net pricing for Cumberland's branded medicines. - **Group purchasing organizations** (secondary) — Large institutional buyers that negotiate access and pricing for hospital systems and outpatient facilities. - **International commercial partners** (secondary) — Licensees and distributors that register and sell Cumberland products outside the U.S. in exchange for milestone or royalty economics. - Wholesale pharmaceutical distributors that buy and resell Cumberland products - Hospitals and health systems that use acute-care injectable brands - Clinics and outpatient centers that purchase through wholesalers or group contracts - Pharmacy benefit managers and payors that influence formulary access and reimbursement - Group purchasing organizations and hospital buying groups that negotiate access - International partners that commercialize products in local markets ## Geography Cumberland is headquartered in the United States and generates most of its commercial activity there, where it promotes products through hospital, field, and oncology sales teams. The company also works through a network of international partners to register and commercialize selected products abroad, which adds milestone and partnership revenue. Recent disclosures mention international progress for Vibativ in China and Saudi Arabia, and ibuprofen product approval in Mexico, showing that non-U.S. markets are part of the growth strategy. Operationally, U.S. distribution is outsourced to Cardinal Health Specialty Solutions, which handles warehousing, shipping, and related logistics. Geography matters because the company’s revenue mix depends on U.S. institutional access while international expansion can add growth but also regulatory and execution risk. - United States is the core commercial market and main source of product sales - U.S. distribution logistics are handled by Cardinal Health Specialty Solutions - International partners support registration and commercialization outside the U.S. - China and Saudi Arabia were highlighted as recent Vibativ expansion markets - Mexico approval expanded the ibuprofen product's Latin American footprint - Geographic expansion can add milestone revenue but increases regulatory complexity ## Strategy Cumberland’s strategy is to grow its approved branded portfolio by improving access, expanding promotion, and supporting products with focused sales efforts in concentrated specialty markets. The company is also pushing international partnerships to extend the reach of existing brands and create additional non-U.S. revenue streams. A second pillar is clinical development, especially around ifetroban, which could add a future pipeline asset beyond the current commercial portfolio. Management also signals openness to selective acquisitions and partnerships, consistent with a business model that supplements internal development with external asset sourcing. This strategy matters because the company depends on a relatively small number of brands, so lifecycle management, access expansion, and new product opportunities are central to offsetting generic pressure and product concentration. - **Grow approved brands in core specialty markets** (short-term) — The company’s near-term cash generation depends on maximizing sales from its existing branded portfolio in concentrated prescriber bases. - **Expand international partnerships and registrations** (medium-term) — International commercialization can extend product life cycles and create milestone or royalty revenue without building a full foreign sales infrastructure. - **Advance ifetroban and other development assets** (medium-term) — A successful pipeline asset could diversify the company beyond mature commercial brands and reduce dependence on a small product set. - **Pursue selective acquisitions and collaborations** (long-term) — External asset sourcing can replenish the portfolio and create new branded opportunities without relying solely on internal discovery. - Expand sales of approved brands in hospital acute care, gastroenterology, and oncology - Use targeted sales forces rather than broad mass-market promotion - Grow international partnerships to add market access and milestone revenue - Advance clinical development programs, including ifetroban - Pursue selective acquisitions to broaden the branded portfolio - Strengthen formulary access and national account relationships ## Risks Cumberland faces the typical risks of a branded pharmaceutical company, including generic competition, pricing pressure, and dependence on formulary access and reimbursement decisions. Because its products are sold through wholesalers and institutional channels, consolidation among distributors and payors can reduce negotiating power and compress net pricing. The company is also exposed to regulatory, product liability, and intellectual property risks, since its value depends on approved products, exclusivity, and successful defense of branded positions. Operationally, supply chain disruptions, inventory availability, and third-party manufacturing or logistics performance can affect sales, as seen in product inventory constraints and delayed international orders. The company also carries development risk in its pipeline and partnership strategy, where clinical or regulatory setbacks could limit future growth. - **Generic substitution and branded product erosion** [high] — Cumberland sells branded prescription medicines in categories where generic alternatives can quickly reduce demand and pricing power. - **Formulary and reimbursement pressure** [high] — Managed care organizations, PBMs, and hospital buyers can restrict access or demand rebates, reducing net revenue. - **Distributor concentration** [high] — A small number of wholesalers represent a large share of revenue, so customer concentration can materially affect sales if purchasing patterns change. - **Regulatory and compliance risk** [high] — The business depends on FDA approvals, labeling, and ongoing compliance with pharmaceutical regulations. - **Product liability and safety claims** [medium] — Prescription medicines can trigger litigation or adverse event-related claims that create legal costs and reputational damage. - **Supply chain and third-party execution** [medium] — The company relies on third-party logistics, manufacturing, and international partners, which can affect inventory and launch timing. - Generic competition can erode branded product sales and reduce return on development and commercialization costs - Formulary exclusion and reimbursement pressure can limit access and lower net pricing - Distributor and payor consolidation can weaken bargaining power and reduce purchase volumes - Regulatory and compliance risk is high because products are prescription medicines sold under FDA oversight - Product liability exposure exists for marketed products and clinical candidates - Supply chain, manufacturing, and third-party logistics disruptions can interrupt product availability - Pipeline and partnership execution risk could delay or prevent future growth from ifetroban and international deals ## Accounting Cumberland’s revenue recognition is judgment-heavy because product sales are recorded at shipment or delivery, but net revenue must be reduced for chargebacks, rebates, coupons, returns, and service fees. That means reported sales depend heavily on estimates of future deductions, and the company explicitly notes that these allowances are determined product by product using historical experience, contract terms, prescription trends, and channel inventory levels. Other revenue is also important because it includes milestone payments, upfront payments, contract services, and rental income, which can create quarter-to-quarter volatility unrelated to product demand. The company also highlights estimates for inventory obsolescence, contingent consideration, and intangible asset utility, all of which can materially affect earnings if product performance or market conditions change. Share-based compensation and R&D accruals add further judgment, especially where clinical work is estimated based on progress rather than completed invoices. - **Revenue deductions and reserves** — Affects reported net sales and receivables - **Other revenue recognition** — Affects quarterly revenue volatility - **Inventory obsolescence** — Affects gross margin and operating income - **Intangible assets and contingent consideration** — Affects impairment risk and acquisition accounting - **R&D accruals and share-based compensation** — Affects operating expenses - Net product revenue is reduced by estimated rebates, chargebacks, discounts, and returns - Revenue is recognized at shipment or delivery depending on shipping terms - Other revenue can include milestone and upfront payments, creating lumpy quarterly results - Allowance estimates are product-specific and depend on channel inventory and prescription trends - Inventory obsolescence reserves matter for products with declining demand or discontinued lines - Contingent consideration and intangible asset valuations can affect earnings after acquisitions - R&D accruals and share-based compensation require management estimates --- *Last updated: 2026-08-11T04:46:27.312306+00:00*